Topical GHK-Cu Gel Explored for Faster Skin Wound Healing in Human Trial

Acute skin wounds, such as those from surgery or injury, present a significant challenge due to the risk of infection, scarring, and prolonged recovery. Current treatments often focus on preventing infection and maintaining a moist wound environment, but there's a continuous need for therapies that can actively accelerate the natural healing process. GHK-Cu (Copper(II)-Peptide Complex) is a naturally occurring peptide known for its roles in tissue regeneration, anti-inflammatory responses, and antioxidant activity, making it a promising candidate for wound care. However, its efficacy and safety as a topical gel specifically for accelerating re-epithelialization of standardized acute skin wounds in healthy adults require rigorous clinical validation.

As of the current record, this study (NCT ID: NCT07437586) is actively RECRUITING participants and is projected for completion by 2028-03-17, meaning no results are available yet. However, the study is designed to rigorously assess several key outcomes. Researchers will primarily measure the time to complete re-epithelialization (the process of new skin growth over a wound), comparing the GHK-Cu treated wounds against the vehicle control. They will also evaluate secondary endpoints such as the rate of wound closure, scar quality using validated scales, and the incidence of adverse events to determine safety and tolerability. The expectation is that GHK-Cu will demonstrate a statistically significant improvement in healing metrics. > The primary objective is to determine if topical GHK-Cu Gel can significantly reduce the time required for complete re-epithelialization of standardized acute skin wounds compared to a vehicle control.